Home Cart Sign in  
Chemical Structure| 1792999-26-8 Chemical Structure| 1792999-26-8

Structure of NCB-0846
CAS No.: 1792999-26-8

Chemical Structure| 1792999-26-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

NCB-0846 is an TNIK inhibitor with IC50 value of 21 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of NCB-0846

CAS No. :1792999-26-8
Formula : C21H21N5O2
M.W : 375.42
SMILES Code : O[C@H]1CC[C@@H](OC2=CC=CC3=CN=C(NC4=CC=C5C(NC=N5)=C4)N=C23)CC1
MDL No. :MFCD30749187
InChI Key :FYWRWBSYRGSWIQ-UHFFFAOYSA-N
Pubchem ID :91801204

Safety of NCB-0846

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293 0.1-0.3 µM 24 hours Inhibition of TCF/LEF transcriptional activity Nat Commun. 2016 Aug 26;7:12586
DLD-1 0.1-0.3 µM 24 hours Inhibition of TCF/LEF transcriptional activity Nat Commun. 2016 Aug 26;7:12586
HCT116 0.1-0.3 µM 24 hours Inhibition of TCF/LEF transcriptional activity Nat Commun. 2016 Aug 26;7:12586
PDX cells 0–10 µM 12 days To assess the effect of NCB-0846 on colony formation, results showed that NCB-0846 significantly reduced colony formation. Neoplasia. 2019 Apr;21(4):389-400
PDX cells 0–10 µM 1-5 days To assess the effect of NCB-0846 on cell viability, results showed that NCB-0846 significantly reduced cell viability. Neoplasia. 2019 Apr;21(4):389-400
PDX cells 0–10 µM 24 hours To assess the effect of NCB-0846 on TNIK and TNIK (pS764) expression, results showed that NCB-0846 significantly decreased TNIK and TNIK (pS764) levels. Neoplasia. 2019 Apr;21(4):389-400
MC3T3-E1 osteoblasts 0.2 µM 24 hours To study the effect of NCB-0846 on collagen deposition in osteoblasts. Results showed that NCB-0846 treatment did not limit collagen deposition. Hepatol Commun. 2022 Mar;6(3):593-609
Primary human hepatic stellate cells 0.1 µM 24 hours To evaluate the inhibition of TNIK kinase activity by NCB-0846 and its effect on procollagen I secretion. It was found that NCB-0846 treatment reduced secretion of collagen I and fibronectin without affecting procollagen I transcription. Hepatol Commun. 2022 Mar;6(3):593-609
LX-2 cells 0.1 µM 24 hours To investigate the inhibitory effect of NCB-0846 on TNIK kinase activity and its impact on procollagen I secretion. Results showed that NCB-0846 treatment limited TNIK autophosphorylation and reduced secretion of collagen I and fibronectin. Hepatol Commun. 2022 Mar;6(3):593-609
PDX cells 0–10 µM 4 weeks To assess the effect of NCB-0846 on anchorage-independent growth in soft agar, results showed that NCB-0846 significantly reduced colony number and size. Neoplasia. 2019 Apr;21(4):389-400
LUDLU1 300 nM 48 hours To evaluate the radiosensitizing effect of NCB-0846 on TNIKlow LSCC cells, results showed that NCB-0846 did not significantly reduce the survival of TNIKlow cells. Mol Cancer Ther. 2024 Apr 27;23(8):1201–11
KNS62 300 nM 48 hours To evaluate the radiosensitizing effect of NCB-0846 on TNIKlow LSCC cells, results showed that NCB-0846 did not significantly reduce the survival of TNIKlow cells. Mol Cancer Ther. 2024 Apr 27;23(8):1201–11
SW900 300 nM 48 hours To evaluate the radiosensitizing effect of NCB-0846 on TNIKhigh LSCC cells, results showed that pretreatment with NCB-0846 significantly reduced the survival of TNIKhigh cells. Mol Cancer Ther. 2024 Apr 27;23(8):1201–11
H520 300 nM 48 hours To evaluate the radiosensitizing effect of NCB-0846 on TNIKhigh LSCC cells, results showed that pretreatment with NCB-0846 significantly reduced the survival of TNIKhigh cells. Mol Cancer Ther. 2024 Apr 27;23(8):1201–11
LK2 300 nM 48 hours To evaluate the radiosensitizing effect of NCB-0846 on TNIKhigh LSCC cells, results showed that pretreatment with NCB-0846 significantly reduced the survival of TNIKhigh cells. Mol Cancer Ther. 2024 Apr 27;23(8):1201–11
NCI-H2228 cells 1 µM 48 hours NCB-0846 modestly inhibited TGF β1-induced EMT in H2228 cells, but the effect on EMT markers was not obvious. Br J Cancer. 2021 Jan;124(1):228-236
A549 cells 1 µM 48 hours NCB-0846 inhibited TGF β1-induced EMT in A549 cells, restored E-cadherin expression, and suppressed mesenchymal markers vimentin and N-cadherin. Br J Cancer. 2021 Jan;124(1):228-236
Aska >2.0 µM 72 hours Evaluate the inhibitory effect of NCB-0846 on Aska cells, results showed IC50 exceeding 2.0 µM, cells were insensitive to the drug Cancers (Basel). 2020 May 16;12(5):1258
Yamato 767 nM 72 hours Evaluate the inhibitory effect of NCB-0846 on Yamato cells, results showed IC50 of 767 nM, significantly inhibiting cell viability Cancers (Basel). 2020 May 16;12(5):1258
SYO-1 356 nM 72 hours Evaluate the inhibitory effect of NCB-0846 on SYO-1 cells, results showed IC50 of 356 nM, significantly inhibiting cell viability Cancers (Basel). 2020 May 16;12(5):1258
HS-SY-II 339 nM 72 hours Evaluate the inhibitory effect of NCB-0846 on HS-SY-II cells, results showed IC50 of 339 nM, significantly inhibiting cell viability Cancers (Basel). 2020 May 16;12(5):1258

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice CCl4-induced liver fibrosis model Intraperitoneal injection 10 mg/kg 5 times per week for 4 weeks To evaluate the inhibitory effect of NCB-0846 on liver fibrosis in vivo. Results showed that NCB-0846 treatment reduced CCl4-induced fibrosis and decreased expression of collagen I and fibronectin. Hepatol Commun. 2022 Mar;6(3):593-609
NOD-scid IL2Rgammanull mice Subcutaneous xenograft model Oral gavage 100 mg/kg Administered on days 1, 3, and 5, lasting for 1 week To evaluate the radiosensitizing effect of NCB-0846 on TNIKhigh LSCC tumors, results showed that pretreatment with NCB-0846 significantly enhanced the efficacy of IR and caused elevated necrosis in TNIKhigh LK2 tumors but not TNIKlow KNS62 tumors. Mol Cancer Ther. 2024 Apr 27;23(8):1201–11
Mice Apcmin/þ mice Oral 22.5-90 mg/kg BID for 35 days Suppression of Wnt-driven intestinal tumorigenesis Nat Commun. 2016 Aug 26;7:12586
SCID mice A549 cell lung metastasis model Tail vein injection 3 µM Single injection, observed for 7 weeks NCB-0846 significantly reduced the metastatic lesion area in the lungs of SCID mice injected with TGF β1-treated A549 cells. Br J Cancer. 2021 Jan;124(1):228-236
NOD/SCID mice Subcutaneous xenograft model Oral 80 mg/kg Twice daily for 5 days Evaluate the inhibitory effect of NCB-0846 on subcutaneous xenografts, results showed significant reduction in tumor volume Cancers (Basel). 2020 May 16;12(5):1258

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.66mL

0.53mL

0.27mL

13.32mL

2.66mL

1.33mL

26.64mL

5.33mL

2.66mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories